Produced in partnership with IBTV, our Roving Reporter series captures real-time perspectives from across the life sciences industry. Filmed on the show floor at ASGCT 2026 in Boston, this episode brings together leading voices from across cell and gene therapy to ask whether the field is moving beyond scientific promise and into a more mature, commercially focused phase.
As cell and gene therapies move closer to routine clinical use, companies are placing greater emphasis on regulatory expectations, manufacturing scalability, cost of goods, supply-chain resilience, and patient access. Portfolio prioritization and sustainable commercialization strategies are also becoming increasingly important, particularly as developers seek to expand these therapeutic modalities beyond rare diseases and into larger patient populations.
Featuring insights from Andrew Scheffler of ScaleReady, Emanuelle Cameau of Cytiva, Nick Randall of Repligen, John Tomtishen of Catalent, David Radspinner of VintaBio, Bryan Deuber of Andelyn, Heather Purvis of Title21 Health Solutions, Natalia Elizalde of VIVEbiotech, Jimmy Vanhove of Viralgen, and Andrew Lewin of Lentitek, the discussion explores how investment decisions, platform technologies, manufacturing innovation, and collaboration across the ecosystem are shaping the next chapter for advanced therapies.
Watch the video below.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
